• Pippa G Corrie, Margaret Moody, Victoria Wood, Linda Bavister, Toby Prevost, Richard A Parker, Ramon Sabes-Figuera, Paul McCrone, Helen Balsdon, Karen McKinnon, Brendan O'Sullivan, Ray S Tan, and Stephen Ig Barclay.
• Oncology Centre, Addenbrooke's Hospital, Cambridge, UK. pippa.corrie@addenbrookes.nhs.uk
• Bmc Cancer. 2011 Oct 29; 11: 467.

BackgroundThe national Cancer Reform Strategy recommends delivering care closer to home whenever possible. Cancer drug treatment has traditionally been administered to patients in specialist hospital-based facilities. Technological developments mean that nowadays, most treatment can be delivered in the out-patient setting. Increasing demand, care quality improvements and patient choice have stimulated interest in delivering some treatment to patients in the community, however, formal evaluation of delivering cancer treatment in different community settings is lacking. This randomised trial compares delivery of cancer treatment in the hospital with delivery in two different community settings: the patient's home and general practice (GP) surgeries.Methods/DesignPatients due to receive a minimum 12 week course of standard intravenous cancer treatment at two hospitals in the Anglia Cancer Network are randomised on a 1:1:1 basis to receive treatment in the hospital day unit (control arm), or their own home, or their choice of one of three neighbouring GP surgeries. Overall patient care, treatment prescribing and clinical review is undertaken according to standard local practice. All treatment is dispensed by the local hospital pharmacy and treatment is delivered by the hospital chemotherapy nurses. At four time points during the 12 week study period, information is collected from patients, nursing staff, primary and secondary care teams to address the primary end point, patient-perceived benefits (using the emotional function domain of the EORTC QLQC30 patient questionnaire), as well as secondary end points: patient satisfaction, safety and health economics.DiscussionThe Outreach trial is the first randomised controlled trial conducted which compares delivery of out-patient based intravenous cancer treatment in two different community settings with standard hospital based treatment. Results of this study may better inform all key stakeholders regarding potential costs and benefits of transferring clinical services from hospital to the community.Trial Registration NumberISRCTN: ISRCTN66219681.

22 keywords...

hide…